Get started
Work

A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

Year: 2021
Type: conference-abstract
Source: Blood
DOI: 10.1182/blood-2021-149797
Authors: Omar Nadeem, Robert A. Redd, Michael Z. Koontz, Jeffrey V. Matous, Andrew J. Yee, Jeffrey A. Zonder, Andrew Kin, Jacalyn Rosenblatt, Julia Prescott, Kelsey Tague, Veronica Romines, Meredith Bertoni, Amada Metivier, Rebekah Medina, Alexandra Savell, Houry Leblebjian, Alexandra Distaso, Clifton C Mo, Jacob P. Laubach, Adam S. Sperling, Paul G. Richardson, Irene M. Ghobrial
Institutions: Dana-Farber Cancer Institute, Colorado Blood Cancer Institute, Massachusetts General Hospital, The Barbara Ann Karmanos Cancer Institute, Wayne State University, Beth Israel Deaconess Medical Center, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard University
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: closed
OpenAlex ID: W3213317752
Cites:
Cited by: 6
Related to: 10